Controversy: To Treat or Not to Treat in Clinically Isolated Syndrome

Rudick Richard A. MD From the Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. Correspondence: Richard A. Rudick, MD, Mellen Center U10, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195; e-mail: rudickr@ccf.org.

The Case for Early Treatment of Clinically Isolated Syndrome with Disease-Modifying Drugs Cottrell David A. MB ChB, MRCP, BSc, PhD From the Department of Neurology, Frenchay Hospital, Bristol, United Kingdom. Correspondence: David A. Cottrell, MB ChB, MRCP, BSc, PhD, Department of Neurology, Frenchay Hospital, Bristol, BS16 1LE, United Kingdom; e-mail: David.Cottrell@nbt.nhs.uk.

The Case for Delaying Treatment of Clinically Isolated Syndrome